Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
Phase 1
Active, not recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT06528093
- Locations
- 🇺🇸
HealthONE, Denver, Colorado, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1000
- Registration Number
- NCT06527846
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06520514
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT06520553
- Locations
- 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands
A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)
Phase 1
Recruiting
- Conditions
- Cystic Fibrosis
- Interventions
- Genetic: BI 3720931Drug: PlaceboDevice: Inhaler
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT06515002
- Locations
- 🇫🇷
HOP Gui de Chauliac, Montpellier, France
🇬🇧University Hospital Llandough, Cardiff, United Kingdom
🇬🇧Queen Elizabeth University Hospital, Glasgow, United Kingdom
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Dabigatran-etexilate
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT06504862
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT06494774
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06494761
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT06492135
- Locations
- 🇨🇳
Shanghai Central Hospital of Xuhui District, Shanghai, China
Real-life-persistence to Antifibrotic Treatments
Active, not recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10646
- Registration Number
- NCT06485635
- Locations
- 🇫🇷
Clinityx, Boulogne-Billancourt, France